US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LeonaBio Inc

7.73

+0.04500.59%

Post-market: 7.730.00000.00%19:30 EDT

Volume:8K

Turnover:65.78K

Market Cap:72.61M

PE:-0.34

High:8.12

Open:7.57

Low:7.55

Close:7.69

52wk High:14.21

52wk Low:3.53

Shares:9.39M

Float Shares:5.65M

Volume Ratio:0.05

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-23.0100

EPS(LYR):-24.7000

ROE:-431.39%

ROA:-74.07%

PB:2.16

PE(LYR):-0.31

Loading ...

Overview Company News Filings

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR), LeonaBio (LONA) and Assertio Therapeutics (ASRT)

LeonaBio files Form 3 for director Peter B. Silverman

LeonaBio Q1 EPS $(1.73) Beats $(2.50) Estimate

Benzinga Earnings

LeonaBio Q1 FY26 net loss widens to $32.9 million; R&D expenses rise to $10.3 million

BRIEF-LeonaBio, Inc Q1 EPS USD -1.73

LeonaBio appoints Callori, Holles and Silverman to board

Press Release: LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.

Mizuho Securities Keeps Their Buy Rating on LeonaBio (LONA)

LeonaBio to host virtual KOL event on lasofoxifene in metastatic breast cancer

LeonaBio presented data on lasofoxifene research at AACR26

LeonaBio says AACR data support ELAINE-3 Phase 3 lasofoxifene breast cancer trial

Eight option delistings on April 20th

LeonaBio (LONA) Gets a Buy from Mizuho Securities

U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio

Leonabio Warns of Major Financial and Operational Risks in Lasofoxifene Program Integration

LeonaBio amends 8-K to report Sermonix deal as business acquisition, adds license exhibit

LeonaBio FY25 net loss widens 9% to $106 million

LeonaBio Inc reports results for the quarter ended December 31 - Earnings Summary

LeonaBio Q4 EPS $(2.77) Misses $(0.84) Estimate

Benzinga Earnings

LeonaBio FY2025 net cash used in operations narrows 52.98% to $45.7 million; net loss per share widens to $24.70

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LONA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LONA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LONA\",,,,,undefined,":{"symbol":"LONA","market":"US","secType":"STK","nameCN":"LeonaBio Inc","latestPrice":7.73,"timestamp":1787601600000,"preClose":7.685,"halted":0,"volume":8429,"hourTrading":{"tag":"盘后","latestPrice":7.73,"preClose":7.73,"latestTime":"19:30 EDT","volume":11,"amount":84.91,"timestamp":1787614206853,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0058555627846455195,"floatShares":5645000,"shares":9393514,"eps":-23.01,"marketStatus":"Not Yet Opened","change":0.045,"latestTime":"08-24 16:00:00 EDT","open":7.57,"high":8.115,"low":7.55,"amount":65781.80409599999,"amplitude":0.07352,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-23.01,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"listingDate":1600401600000,"exchange":"NASDAQ","adjPreClose":7.685,"postHourTrading":{"tag":"盘后","latestPrice":7.73,"preClose":7.73,"latestTime":"19:30 EDT","volume":11,"amount":84.91,"timestamp":1787614206853,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.050865},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LONA\",,,,,undefined,":{"symbol":"LONA","floatShares":5645000,"roa":"-74.07%","roe":"-431.39%","lyrEps":-24.699999,"volumeRatio":0.050865,"shares":9393514,"dividePrice":0,"high":8.115,"amplitude":0.07352,"preClose":7.685,"low":7.55,"week52Low":3.525,"pbRate":"2.16","week52High":14.21,"institutionHeld":0,"latestPrice":7.73,"eps":-23.01,"divideRate":0,"volume":8429,"delay":0,"ttmEps":-23.01,"open":7.57,"prevYearClose":7.57,"prevWeekClose":7.685,"prevMonthClose":7.06,"prevQuarterClose":9.19,"fiveDayClose":7.71,"twentyDayClose":7.36,"sixtyDayClose":9.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LONA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"LONA","fiscalQuarterEnding":"2026/06","expectedEps":-1.9,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"post","actualEps":-0.8},{"market":"US","date":"2026-05-07","symbol":"LONA","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-1.73},{"market":"US","date":"2026-03-26","symbol":"LONA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-06","symbol":"LONA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-1.68},{"market":"US","date":"2025-09-18","symbol":"LONA","defaultRemindTime":1758202200000,"type":"split","dateTimestamp":1758168000000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LONA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LONA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1785643200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LONA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LONA","date":"2026-08-21","current":-0.335941,"percent":0.986755,"low":-2.796591,"twenty":-1.23248,"median":-0.741811,"eighty":-0.606085,"high":-0.505917,"avg":-0.940763,"sd":0.479287,"marketCap":72330057},"quantilePoints":[{"date":"2026-01-16","current":-0.662315,"twenty":-0.686048,"median":-0.684271,"eighty":-0.675175,"marketCap":24984524},{"date":"2026-01-23","current":-1.56325,"twenty":-0.686675,"median":-0.673032,"eighty":-0.651338,"marketCap":58970481},{"date":"2026-01-30","current":-1.165659,"twenty":-1.344824,"median":-0.68793,"eighty":-0.65761,"marketCap":43972150},{"date":"2026-02-06","current":-1.185458,"twenty":-1.276038,"median":-1.158235,"eighty":-0.670888,"marketCap":44719023},{"date":"2026-02-13","current":-1.158234,"twenty":-1.22753,"median":-1.158234,"eighty":-0.684166,"marketCap":43692072},{"date":"2026-02-20","current":-1.368597,"twenty":-1.23248,"median":-1.158234,"eighty":-0.68542,"marketCap":51627598},{"date":"2026-02-27","current":-1.390871,"twenty":-1.374537,"median":-1.170609,"eighty":-0.765162,"marketCap":52467831},{"date":"2026-03-06","current":-1.329,"twenty":-1.392851,"median":-1.185458,"eighty":-1.076564,"marketCap":50133852},{"date":"2026-03-13","current":-1.856145,"twenty":-1.437398,"median":-1.225055,"eighty":-1.089928,"marketCap":70019347},{"date":"2026-03-20","current":-2.457536,"twenty":-1.517584,"median":-1.326525,"eighty":-1.109727,"marketCap":92705616},{"date":"2026-03-27","current":-2.395664,"twenty":-1.826942,"median":-1.36281,"eighty":-1.136951,"marketCap":90371637},{"date":"2026-04-02","current":-0.885775,"twenty":-1.710128,"median":-1.327762,"eighty":-1.074089,"marketCap":93545848},{"date":"2026-04-10","current":-0.848546,"twenty":-1.591335,"median":-1.23743,"eighty":-0.90876,"marketCap":89614123},{"date":"2026-04-17","current":-0.732027,"twenty":-1.56325,"median":-1.192883,"eighty":-0.852104,"marketCap":77308620},{"date":"2026-04-24","current":-0.766716,"twenty":-1.526988,"median":-1.173083,"eighty":-0.820084,"marketCap":80972090},{"date":"2026-05-01","current":-0.80941,"twenty":-1.479966,"median":-1.161946,"eighty":-0.806742,"marketCap":85480977},{"date":"2026-05-08","current":-0.877009,"twenty":-1.479232,"median":-1.15081,"eighty":-0.806742,"marketCap":92620048},{"date":"2026-05-15","current":-0.798435,"twenty":-1.470067,"median":-1.095125,"eighty":-0.784505,"marketCap":103328654},{"date":"2026-05-22","current":-0.730931,"twenty":-1.437893,"median":-1.038891,"eighty":-0.766716,"marketCap":94592685},{"date":"2026-05-29","current":-0.699719,"twenty":-1.435914,"median":-0.977518,"eighty":-0.742344,"marketCap":90553474},{"date":"2026-06-05","current":-0.624957,"twenty":-1.41958,"median":-0.881392,"eighty":-0.732312,"marketCap":80878155},{"date":"2026-06-12","current":-0.616247,"twenty":-1.397801,"median":-0.861888,"eighty":-0.723673,"marketCap":79750933},{"date":"2026-06-18","current":-0.597374,"twenty":-1.391861,"median":-0.852104,"eighty":-0.699139,"marketCap":77308620},{"date":"2026-06-26","current":-0.630764,"twenty":-1.383447,"median":-0.845878,"eighty":-0.684375,"marketCap":81629636},{"date":"2026-07-02","current":-0.608262,"twenty":-1.377507,"median":-0.836094,"eighty":-0.66996,"marketCap":78717647},{"date":"2026-07-10","current":-0.681573,"twenty":-1.373052,"median":-0.819033,"eighty":-0.654571,"marketCap":88205096},{"date":"2026-07-17","current":-0.566889,"twenty":-1.363967,"median":-0.812078,"eighty":-0.651338,"marketCap":73363344},{"date":"2026-07-24","current":-0.525515,"twenty":-1.345814,"median":-0.798435,"eighty":-0.635734,"marketCap":68009041},{"date":"2026-07-31","current":-0.529145,"twenty":-1.328505,"median":-0.788063,"eighty":-0.629457,"marketCap":68478717},{"date":"2026-08-07","current":-0.566889,"twenty":-1.323555,"median":-0.7765,"eighty":-0.623505,"marketCap":73363344},{"date":"2026-08-14","current":-0.571244,"twenty":-1.296827,"median":-0.749803,"eighty":-0.613488,"marketCap":73926955},{"date":"2026-08-21","current":-0.511329,"twenty":-1.23248,"median":-0.741811,"eighty":-0.606085,"marketCap":72330057}],"updateTime":1787629657729},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LONA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2634280740","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR), LeonaBio (LONA) and Assertio Therapeutics (ASRT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634280740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634280740?lang=en_us&edition=fundamental","pubTime":"2026-05-11 22:30","pubTimestamp":1778509851,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cencora (COR), LeonaBio (LONA) and Assertio Therapeutics (ASRT). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cencora-cor-leonabio-lona-and-assertio-therapeutics-asrt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cencora-cor-leonabio-lona-and-assertio-therapeutics-asrt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","HCSG","BK4007","LENZ","BK4588","XBI","LU1430594728.SGD","LU1814569148.SGD","BK4529","LU2237957902.USD","SG9999004303.SGD","LU0058720904.USD","COR","LU0128526141.USD","BK4581","LU0029874061.USD","SGXZ23171101.USD","BK4084","LU1084165304.USD","LU2237957811.SGD","LU1261432733.SGD","BK4175","LU2324357040.USD","LU0289739699.SGD","XLV","BK4139","LABU","LU1585245621.USD","LU1119994496.HKD","ASRT","BK4585","LONA","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633109472","title":"LeonaBio files Form 3 for director Peter B. Silverman","url":"https://stock-news.laohu8.com/highlight/detail?id=2633109472","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633109472?lang=en_us&edition=fundamental","pubTime":"2026-05-08 08:24","pubTimestamp":1778199890,"startTime":"0","endTime":"0","summary":"LeonaBio director Peter B. Silverman filed an initial Form 3 beneficial ownership statement dated May 5.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeonaBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL38MpWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LONA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633467172","title":"LeonaBio Q1 EPS $(1.73) Beats $(2.50) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633467172","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633467172?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:44","pubTimestamp":1778186652,"startTime":"0","endTime":"0","summary":"LeonaBio (NASDAQ:LONA) reported quarterly losses of $(1.73) per share which beat the analyst consensus estimate of $(2.50) by 30.8 percent. This is a 26.07 percent increase over losses of $(2.34) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52392996/leonabio-q1-eps-1-73-beats-2-50-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LeonaBio Q1 EPS $(1.73) Beats $(2.50) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LONA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633174552","title":"LeonaBio Q1 FY26 net loss widens to $32.9 million; R&D expenses rise to $10.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633174552","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633174552?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:27","pubTimestamp":1778185652,"startTime":"0","endTime":"0","summary":"LeonaBio reported a net loss of $32.9 million, or $1.73 per share, for the quarter ended March 31, 2026, widening from a $9.1 million loss a year earlier.R&D expenses jumped to $10.3 million from $4.3 million, while G&A costs rose to $6.9 million from $5.2 million.Cash, cash equivalents and investments fell to $67.7 million at March 31 from $88.3 million at year-end 2025, with net cash used in operations increasing to $20.9 million from $14.7 million a year earlier.Phase 3 ELAINE-3 trial protocol for lasofoxifene is being amended to raise planned enrollment to up to 600 patients from 500, with enrollment expected to complete in 4Q 2026 and topline data anticipated in 2H 2027.Phase 2 proof-of-concept study of ATH-1105 in ALS remains on track to begin dosing patients in 2H 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL65bzZk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014005.SGD","LU2210149790.SGD","BK4007","NDAQ","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4585","BK4112","IE00BKPKM429.USD","SG9999014021.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LONA","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633179525","title":"BRIEF-LeonaBio, Inc Q1 EPS USD -1.73","url":"https://stock-news.laohu8.com/highlight/detail?id=2633179525","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633179525?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:05","pubTimestamp":1778184355,"startTime":"0","endTime":"0","summary":"BRIEF-LeonaBio, Inc Q1 EPS USD -1.73\n\n\nMay 07 (Reuters) - LeonaBio, Inc Q1 operating expenses USD 17.214 million.\n\nQ1 net income USD -32.948 million\nQ1 operating income USD -17.214 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX0393E9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633815128","title":"LeonaBio appoints Callori, Holles and Silverman to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2633815128","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633815128?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:20","pubTimestamp":1778160030,"startTime":"0","endTime":"0","summary":"LeonaBio appointed Fred Callori, Natalie Holles, Peter B. Silverman to board, effective May 5, 2026.Callori is partner and managing director at Perceptive Advisors, previously held senior corporate development roles at life sciences accelerator Xontogeny.Holles is CEO of Aura Biosciences, previously led Third Harmonic Bio, previously held senior operating and corporate development roles at Audentes Therapeutics, Hyperion Therapeutics, Immune Design.Silverman previously served as COO of Merus until its acquisition by Genmab in December 2025, previously was Merus general counsel, earlier was partner at Kirkland & Ellis.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL5FzhsG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU0238689110.USD","LU0265550946.USD","LU2491050071.SGD","IE00BJJMRZ35.SGD","LU1989772923.USD","SG9999014542.SGD","BK4559","LU1066051811.HKD","BK4585","LU2210150020.SGD","LU0861579265.USD","IE00BLSP4452.SGD","LU2491049909.HKD","LU1201861249.SGD","LU1093756325.SGD","LU1974910355.USD","SG9999002224.SGD","SG9999015358.SGD","BK4566","LU0266013472.USD","LU2324357040.USD","LU0320765646.SGD","LU2089984988.USD","LU0942090050.USD","LU0868494617.USD","LU1571399168.USD","LU1037948897.HKD","SG9999014005.SGD","LU1699723380.USD","LU0106261372.USD","LU2023250504.SGD","LU1941712264.USD","LU0234572021.USD","SG9999014559.SGD","SG9999014013.SGD","LU0098860793.USD","IE00BBT3K403.USD","SG9999013999.USD","LU2361044949.HKD","BK4533","LU0859254822.USD","SG9999014575.USD","BK4516","LU0980610538.SGD","SG9999002232.USD","SG9999014567.USD","LU0109394709.USD","LU1989771016.USD","LU2461242641.AUD","LU1037948541.HKD","SG9999001176.USD","LU0203347892.USD","BK4007","SG9999015341.SGD","IE00BN0W2W23.USD","LU2125154778.USD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE0002141913.USD","LU1983299246.USD","LU0130102774.USD","LU2106854487.HKD","BK4112","LU1430594728.SGD","LU0965509010.AUD","IE0009355771.USD","LU2360032135.SGD","LU2468319806.SGD","LU0070302665.USD","LU1069347547.HKD","IE00BN0W2T93.GBP","LU2361045086.USD","IE00BLSP4239.USD","LU0203345920.USD","LU2095319765.USD","LU1116320737.USD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU1116320901.HKD","IE00B64PRP62.GBP","IE00BSNM7G36.USD","LU1934455863.HKD","BK4588","SGXZ57979304.SGD","LU0965508806.USD","LU0889565916.HKD","IE00BN8TJ469.HKD","LU0648001328.SGD","LU1066051498.USD","LU0289739699.SGD","LU0985320562.USD","LU1093756168.USD","LU0868494708.USD","LU2125154935.USD","BK4534","LU2023250843.SGD","LU0208291251.USD","LU1585245621.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BN0W2V16.EUR","LU0965509283.SGD","LU1066051225.USD","LU0122379950.USD","LU0432979614.USD","LU1941712348.USD","LONA","IE000M9KFDE8.USD","LU2242652126.USD","LU1061106388.HKD","LU1291159041.SGD","LU0477156953.USD","SG9999014039.USD","LU0006306889.USD","LU0320765489.SGD","BK4581","LU1035773651.USD","SG9999001440.SGD","LU1917777945.USD","IE00B1BXHZ80.USD","LU2491050154.USD","LU1162221912.USD","LU1066053197.SGD","LU2112291526.USD","LU0965509101.SGD","LU1057294990.SGD","LU2210149790.SGD","LU2242646821.SGD","SG9999001176.SGD","LU2357627491.SGD","LU1934455194.USD","LU0058720904.USD","LU0265550359.USD","BK4139","BK4550","LU1929549753.HKD","IE00B4R5TH58.HKD","LU0130517989.USD","LU0211331839.USD","LU1934455277.USD","LU1989772840.SGD","LU0314104364.USD","LU2361044865.SGD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128891","title":"Press Release: LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128891","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633128891?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:20","pubTimestamp":1778160000,"startTime":"0","endTime":"0","summary":"\"We are delighted to welcome Fred, Natalie, and Peter to LeonaBio's Board of Directors,\" said Mark Litton, Ph.D., President and Chief Executive Officer of LeonaBio. \"Collectively, they bring significant drug development experience across different oncology and neurology settings, proven leadership in corporate strategy and operational execution, and capital markets expertise. Their backgrounds and capabilities are directly aligned with our clinical focus and will be instrumental as we advance our pipeline and position the company for its next phase of growth.\". \"On behalf of the Board of Directors and management team, I would also like to express our sincere appreciation to John Fluke for his thoughtful counsel and dedicated service over the past decade. His contributions have helped shape LeonaBio into the company it is today,\" added Dr. Litton.Ms. Holles has served as the Chief Executive Officer and member of the Board of Directors of Aura Biosciences, a clinical-stage biotechnology ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632489776","title":"Mizuho Securities Keeps Their Buy Rating on LeonaBio (LONA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632489776","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632489776?lang=en_us&edition=fundamental","pubTime":"2026-05-01 22:36","pubTimestamp":1777646183,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on LeonaBio today and set a price target of $16.00. Suvannavejh covers the Heal...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-leonabio-lona-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-keeps-their-buy-rating-on-leonabio-lona-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","LONA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629615868","title":"LeonaBio to host virtual KOL event on lasofoxifene in metastatic breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2629615868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629615868?lang=en_us&edition=fundamental","pubTime":"2026-04-24 04:14","pubTimestamp":1776975294,"startTime":"0","endTime":"0","summary":"LeonaBio scheduled virtual key opinion leader webinar on April 29, 2026 at 12:00 p.m. ET to discuss lasofoxifene in treatment-resistant ER+/HER2-, ESR1-mutated metastatic breast cancer.Webinar to feature oncology consultant David Portman alongside physician experts Matthew P. Goetz, Seth Wander.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLkf4V3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629031502","title":"LeonaBio presented data on lasofoxifene research at AACR26","url":"https://stock-news.laohu8.com/highlight/detail?id=2629031502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629031502?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:33","pubTimestamp":1776774782,"startTime":"0","endTime":"0","summary":"LeonaBio (LONA) attended the American Association for Cancer Research Annual Meeting 2026, AACR26, where independent researchers at Virginia Common...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leonabio-presented-data-on-lasofoxifene-research-at-aacr26-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leonabio-presented-data-on-lasofoxifene-research-at-aacr26-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033379","title":"LeonaBio says AACR data support ELAINE-3 Phase 3 lasofoxifene breast cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033379","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629033379?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:03","pubTimestamp":1776769424,"startTime":"0","endTime":"0","summary":"LeonaBio highlighted independent nonclinical lasofoxifene findings already presented at AACR 2026.Data supported lasofoxifene potential to preserve bone integrity while sustaining anti-tumor activity in animal models of ER-positive breast cancer, including metastatic settings.Results aligned with LeonaBio ongoing ELAINE-3 Phase 3 study of lasofoxifene in metastatic ER-positive breast cancer patients with ESR1 mutations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeonaBio Inc. published the original content used to generate this news brief on April 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL56tRpQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628972359","title":"Eight option delistings on April 20th","url":"https://stock-news.laohu8.com/highlight/detail?id=2628972359","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628972359?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:31","pubTimestamp":1776688279,"startTime":"0","endTime":"0","summary":"Option delistings effective April 20th include Leonabio, Inc. (LONA), Light & Wonder Inc (LNWO), Heritage Commerce (HTBK), Captivision Inc (CPTAF),...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eight-option-delistings-on-april-20th-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eight-option-delistings-on-april-20th-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4086","CPTAF","LONA","LNWO","HTBK","BK4211","BK4007","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625675163","title":"LeonaBio (LONA) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2625675163","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625675163?lang=en_us&edition=fundamental","pubTime":"2026-04-06 18:37","pubTimestamp":1775471850,"startTime":"0","endTime":"0","summary":"In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on LeonaBio, with a price target of $16.00. Suvannavej...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/leonabio-lona-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/leonabio-lona-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LONA","MFG","BK4207","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625062049","title":"U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio","url":"https://stock-news.laohu8.com/highlight/detail?id=2625062049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625062049?lang=en_us&edition=fundamental","pubTime":"2026-04-06 16:06","pubTimestamp":1775462816,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, TwilioApril 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including EQT, Las Vegas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL8N40P08F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOOT","TRDA","LVS","AMDL","COHU","EVR","GSX","KTUP","LPLA","AYI","LNN","PRIM","AEYE","CAR","AMUU","NXST","AMDY","AMD","LAZ","LONA","NTRS","DELL","IBKR","ADM","NUVB","PJT","SCHW","AMKR","AMP","EXPE","DAMD","AMDU","DLLL","POWI","MC","BKNG","EQT","GLW","MRK","BK","AMYY","LPCN","AMDW","AMDG","CCO","DOW","ASH","BKNU","HLI","KTOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624757887","title":"Leonabio Warns of Major Financial and Operational Risks in Lasofoxifene Program Integration","url":"https://stock-news.laohu8.com/highlight/detail?id=2624757887","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624757887?lang=en_us&edition=fundamental","pubTime":"2026-04-02 14:01","pubTimestamp":1775109707,"startTime":"0","endTime":"0","summary":"Leonabio, Inc. (LONA) has disclosed a new risk, in the Innovation / R&D category. Leonabio, Inc. faces significant uncertainty in successfully inte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/leonabio-warns-of-major-financial-and-operational-risks-in-lasofoxifene-program-integration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/leonabio-warns-of-major-financial-and-operational-risks-in-lasofoxifene-program-integration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624584568","title":"LeonaBio amends 8-K to report Sermonix deal as business acquisition, adds license exhibit","url":"https://stock-news.laohu8.com/highlight/detail?id=2624584568","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624584568?lang=en_us&edition=fundamental","pubTime":"2026-04-01 10:02","pubTimestamp":1775008945,"startTime":"0","endTime":"0","summary":"LeonaBio filed Amendment No. 2 to its Dec. 18, 2025 Form 8-K to reclassify Sermonix transaction as a business acquisition under Item 2.01.SEC staff view triggered waiver under Regulation S-X Rule 3-13, removing requirement to file Sermonix financial statements under Item 9.01 and .Updated disclosure shows Sermonix spent about $14 million in 2023, $12 million in 2024, $5 million through Dec. 18, 2025 on ELAINE-3 study cash outlays.LeonaBio recorded about $11 million in ELAINE-3 cash expenditures from Dec. 18 to Dec. 31, 2025.Company forecast calls for about $45 million in 2026 cash expenditures, about $30 million in 2027 for ELAINE-3.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeonaBio Inc. published the original content used to gen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL57wB1g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537236","title":"LeonaBio FY25 net loss widens 9% to $106 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537236","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537236?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:13","pubTimestamp":1774988028,"startTime":"0","endTime":"0","summary":"LeonaBio posted a net loss of $110 million, widening 9%.Cash, cash equivalents, investments totaled $88 million, following a private placement that raised gross proceeds of about $90 million.Management expects existing cash to fund operating expenses and capital expenditure requirements through at least the next 12 months following the date of the report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LeonaBio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL2SMVwg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LONA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622826947","title":"LeonaBio Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622826947","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622826947?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:00","pubTimestamp":1774612803,"startTime":"0","endTime":"0","summary":"LeonaBio Inc reports results for the quarter ended December 31 - Earnings SummaryLeonaBio Inc LONA.OQ reported a quarterly adjusted loss of $3.46 per share for the quarter ended December 31, higher th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F0V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LONA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891437","title":"LeonaBio Q4 EPS $(2.77) Misses $(0.84) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891437","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891437?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:15","pubTimestamp":1774559715,"startTime":"0","endTime":"0","summary":"LeonaBio (NASDAQ:LONA) reported quarterly losses of $(2.77) per share which missed the analyst consensus estimate of $(0.84) by 229.76 percent. This is a 28.97 percent increase over losses of $(3.90) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51497693/leonabio-q4-eps-2-77-misses-0-84-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LeonaBio Q4 EPS $(2.77) Misses $(0.84) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622789119","title":"LeonaBio FY2025 net cash used in operations narrows 52.98% to $45.7 million; net loss per share widens to $24.70","url":"https://stock-news.laohu8.com/highlight/detail?id=2622789119","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622789119?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:11","pubTimestamp":1774559480,"startTime":"0","endTime":"0","summary":"LeonaBio filed a Form 8-K reporting full-year results, including a net loss of USD 105.6 million, or USD 24.70 per share.Cash, cash equivalents and investments were USD 88.3 million, up 72.1%.R&D expenses were USD 85.6 million, up 21.1%, driven primarily by acquired in-process R&D costs related to the lasofoxifene license.G&A expenses were USD 16.7 million, down 36.0%, driven primarily by cost efficiencies as the company pursued strategic alternatives.Mark Litton said the company expects to complete enrollment in the Phase 3 ELAINE-3 trial in 4Q 2026 with topline data anticipated in 2H 2027, and remains on track to initiate a Phase 2 proof-of-concept study of ATH-1105 in ALS patients in 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL275kYy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LONA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49,"code":"91000000","status":"200"}]}}